Scarica l'app Stockscreener
21.06
2.73%
0.56
Dopo l'orario di chiusura:
21.10
0.04
+0.19%
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
DBV technologies S.A. (ADR) (DBV1.SG) Stock Major Holders - Yahoo! Finance Canada
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday - Defense World
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 - GlobeNewswire Inc.
DBV technologies S.A. (ADR) (DBV1.SG) Stock Forum & Discussion - Yahoo! Finance Canada
Guggenheim Reiterates “Buy” Rating for DBV Technologies (NASDAQ:DBVT) - Defense World
Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
DBV Technologies Reports Full Year 2025 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document - The Manila Times
DBV Technologies (NASDAQ: DBVT) deepens 2025 loss but funds runway into 2027 - Stock Titan
DBV files annual report in the US and France, including buyback plan - Stock Titan
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - Bitget
DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT - Defense World
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
DBV Technologies to Participate in Upcoming March Investor Conferences - The Manila Times
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
Guggenheim Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT) - theglobeandmail.com
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
European ADRs Were Flat As Biotech Names Took The Lead - Finimize
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
DBV Technologies launches $150M ATM offering - MSN
BioImpact LLC reports 9.99% DBV Technologies (DBVT) stake via shares and warrants - Stock Titan
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
DBV Technologies to Participate in Biotech Summit - Intellectia AI
DBV Technologies to Present VIASKIN® Data at AAAAI 2026 - Intellectia AI
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies S.A. - Via Ritzau
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - markets.businessinsider.com
DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
European ADRs Slip As Winners And Losers Split By Region - Finimize
European ADRs Inched Higher As GSK And Telefonica Jumped - Finimize
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):